

Improving Care of Dementia: The Path Forward

September 2023

AVONDALE PARTNERS

September 2023

Introduction



- Alzheimer's is among the costliest diseases in the U.S. with an annual direct cost of \$345 billion, second only to diabetes¹
- Though cognitive impairment ("CI"), and its severest form, Alzheimer's, is recognized as the most debilitating chronic disease, until recently little progress has been made in improving care for individuals with CI
- With improved understanding of the over 50 risk factors of CI, there
 has recently been important technology-driven breakthroughs in early
 diagnosis, care and pharmaceutical treatment of the disease
- Though there is no cure, these recent developments, and many more under research, promise to better diagnose and delay the onset of the most serious symptoms and provide better care for these individuals




This sector insight reviews the breadth of this chronic disease, its financial impact for both the healthcare system and caregivers, and discusses some of the breakthrough technologies and care providers that are beginning to change the face of this disease

September 2023

Improving Care of Dementia: The Path Forward

Due to recent research discoveries and the approval of several new Alzheimer's drugs, the standard treatment of patients with Cognitive Decline is rapidly evolving



September 2023

What is Cognitive Decline?

Cognitive Decline develops over a period of 20–30 years, increasing in severity over time if left untreated¹...

~2 out of 3 Americans will experience Cognitive Decline in their lifetime²...

~1 in 3 Americans age 65 or older have Mild Cognitive Impairment or Alzheimer's/ Dementia – or ~18 million **Americans**

Cognitive Decline ("CD"), also known as Cognitive Impairment, affects a person's memory, language, thinking, or judgement to a greater degree than with normal aging and ranges in severity

Normal Cognitive Function

Mild

Cognitive

Impairment

Dementia

Severe

Dementia

- Subjective Cognitive Impairment ("SCI") includes normal aging individuals as well as those who are progressively becoming more impaired due to a cognitive disorder
- Mild Cognitive Impairment ("MCI") decline in cognitive abilities that is not due to normal aging, but individuals with MCI can still perform daily tasks independently
- Over 12 million Americans have MCl²
- For those that progress to Alzheimer's disease, the MCI stage lasts an average of 7 years³
- **Dementia** higher severity than MCI, where individuals progressively have trouble performing daily tasks and caring for themselves independently
- Over 6 million Americans have Alzheimer's and related dementias, and is expected Mild/Moderate to grow to over 12 million by 2050⁴
 - Alzheimer's disease is the most common form of dementia, accounting for ~60-80% of cases¹
 - For those that progress to Alzheimer's disease, the dementia stage lasts an average of 7 years³


Source: (1) Nature Aging - Towards a future where AD pathology is stopped before the onset of dementia (2) SSM Population Health - Cognitive Impairment in the U.S. (3) hoag.org -Cognitive Severity Stages (Normal Aging - Dementia) (4) Alzheimer's Association


Financial Impact of Cognitive Decline

Direct cost of care of **\$345 billion** attributed to dementia is larger than any other disease, and will grow significantly with the aging population...

2023 estimated Medicare and Medicaid costs attributable to Alzheimer's and dementia represent **~12%** of all Medicare and Medicaid projected expenditures¹...

\$685 billion – Direct and indirect cost of care provided to Americans with Alzheimer's in 2022² The total direct cost of care for patients suffering from Alzheimer's or other dementias is expected to reach \$345 billion in 2023, costing Medicare and Medicaid ~\$222 billion for these patients alone²






Source: (1) Office of the Actuary in the Centers for Medicare & Medicaid Services – NHE Projections Forecast Summary (2) Alzheimer's Association – 2023 Alzheimer's Disease Facts and Figures, (3) "Changing the Trajectory of Alzheimer's Disease" Alzheimer's Association, 2015. (4) Other includes private insurance, HMO, other managed care and uncompensated care


Financial Impact of Cognitive Decline

Dementia's total cost over the last 5 years of life far exceeds the top 2 leading causes of death...

People with Alzheimer's and dementia have substantially higher use of healthcare services...

Many of the expenses associated with Alzheimer's and dementia are uninsured, thus placing a large financial burden on families¹





Source: (1) Annals of Internal Medicine – The Burden of Health Care Costs For Patients With Dementia in the Last 5 Years of Life (2) Alzheimer's Association – 2023 Alzheimer's Disease Facts and Figures,

Progression of Cognitive Decline Treatment

Cognitive

Decline Care

Progression

Historically, Alzheimer's and dementia patients were treated with medications to manage symptoms and told to "get their affairs in order"...

Today, there is a much better understanding of the potential causes of cognitive decline...

Increased awareness and funding across the CD care continuum has prompted innovations in the diagnosis and treatment of patients with CD Physicians previously had little understanding of CD, and diagnosis only occurred once individuals reached the severe phases of Alzheimer's

Physicians who had identified patients with CD only sought to ease symptoms, not address treatable causes

Risk Factors

Cognitive Decline is a complex condition and great strides have been made in identifying over 50 risk factors that contribute to the disease

Diagnostics

Advancements in diagnostic technology allow for earlier detection of CD risks, which is vital to treatment and preventing/delaying disease progression

Care

Identification of risk factors has enhanced the ability to address treatable causes in order to manage symptoms and slow progression of CD

Pharmaceuticals

Currently there is no cure for Alzheimer's and other dementias, but several drugs have been developed which help improve symptoms or slow disease progression

September 2023

Known Risk Factors Of Cognitive Decline


There are 50+ known risk factors of CD that, if addressed can slow or eliminate certain symptoms of Alzheimer's and dementia...

12 modifiable risk factors account for ~40% of worldwide dementias²...

The ability to treat cognitive decline is a recent discovery and an important step in fighting what was previously known as an untreatable disease Non-modifiable risk factors account for some of the greatest risks in developing Alzheimer's and dementia

Age is the greatest risk factor, with ~33% of people age 85+ having Alzheimer's, followed by genetics and family history¹

Despite the impact of non-modifiable risk factors, a growing body of evidence indicates that modifiable risk factors play a significant role in developing Alzheimer's disease



Source: (1) Alzheimer's Association – 2023 Alzheimer's Disease Facts and Figures, (2) Lancet Commission – Dementia Prevention, Intervention, and Care (3) Females are more likely to be diagnosed with cognitive decline, as compared with males (4) Elderly patients taking at least 5 medications are at increased risk of cognitive decline

September 2023

9

Diagnosing Cognitive Decline

Stigmas surrounding dementia, along with misconceptions that	 Screening for CD is required by Medicare as part of annual wellness visits, but current definitive diagnostics tend to be very invasive and cost prohibitive¹ Prior to a definitive diagnostic test, patients must take a simple pen-and-paper cognitive assessment to determine whether they may have cognitive decline 		
it is a natural part of aging, have caused worldwide underdiagnosis	Current Definitive	Cerebrospinal Fluid Extraction	CT Scans
	Diagnostic Technologies	PET Scans ²	MRI Scans

Routine definitive testing for CD will require novel diagnostic approaches offering scalable, repeatable, more cost-effective solutions

Novel diagnostics have yet to receive FDA approval or CMS reimbursement •



Innovations in definitive diagnostic technologies will enable more patients to better address their treatable causes at an earlier disease state

Early diagnosis is key to

progression...

preventing or delaying disease

Cognitive Decline Diagnostic & Assessment Companies

The global cognitive assessment market was valued at \$3.9 billion in 2022, and is expected to grow to \$29.7 billion by 2030, growing at a CAGR of 29.2%¹

Company	Description	Total Amount Raised	Selected Investors
altoida	Developer of brain health assessment and neurocognitive test platform for detecting Alzheimer's and dementia	\$21.3mm	Eisai Innovation; Hikma Ventures; M Ventures; Alzheimer's Drug Discovery Foundation
Brain Check	Platform including comprehensive cognitive and behavioral health assessment, clinical decision support, and cognitive care planning	\$27.1mm	Gershon Capital; UPMC Enterprises; Next Coast Ventures; Nueterra Capital; GOOSE Capital
C2N DIAGNOSTICS	Diagnostics company offering high-resolution mass spectrometry-based biomarker services focused on Alzheimer's	\$35.0mm	Alzheimer's Drug Discovery Foundation; NIH; GHR Foundation
	Digital platform including assessments, clinical decision support, and personalized action planning for those with cognitive decline	\$64.8mm	Morningside Group
88 neurotrack	Platform offers cognitive health programs to assess, preserve and strengthen memory health to reduce risk of future cognitive decline	\$57.6mm	Johnson & Johnson; Founders Fund; Khosla Ventures; AME Cloud Ventures; NIH
Quest Diagnostics ^{**}	World's leading provider of diagnostic testing and information services	Public	Public

September 2023

Addressing Cognitive Decline Through Care Planning

Reimbursable care planning is emerging as a major treatment pathway that can address the modifiable risk factors of cognitive decline...

Specific changes can more effectively slow or alter the progression of cognitive decline...

Detailed care plans proactively address cognitive decline through effective combinations of treatments, lifestyle changes, supplements and medications CMS recognizes the growing problems associated with cognitive decline, and in 2018 created CPT code 99483 to reimburse physicians for developing written care plans for patients at risk of CD

• Leveraging diverse patient data to create personalized cognitive care plans provides a proactive treatment solution to patients

Analyzing & Prioritizing Patient Data Based on Risk Desting Results Cognitive, genomic, blood, sleep, & urine tests Neuropsychiatric & behavioral tests Functional assessments Brain imaging tests Diabetes, hypertension, & obesity Head injury Depression Hearing impairment Medications that affect cognitive function and/or adversely affect other risk factors

Lifestyle Factors

- Exercise & Dietary Habits
- Education Level

•

- Frequency of Social Contact
- Smoking & Alcohol Use

Devise Care Plan to Address Risks

Issues for Physician Follow-Ups

- Addressing medication side effects that mimic symptoms of dementia
- Other medical issues to address

Additional Diagnostic Tests

Other diagnostic tests that can be determine additional risk factors

Pharmaceutical Treatments

- Potential prescriptions, over-the-counter drugs, or supplements that could alleviate certain risk factors
- Determining eligibility for novel treatments like Aduhelm, Leqembi, or Donanemab

Lifestyle Recommendations

- Stress reduction techniques
- Treating sleep apnea
- Fasting
- Implementing an exercise regimen
- Brain stimulation techniques
- Detailed dietary recommendations

September 2023

Cognitive Decline Care Planning Companies

Despite nearly 18 million Americans suffering from MCI and Alzheimer's, only ~83,000 care plans were submitted for reimbursement by CMS in 2021¹

- This massive unmet need can be attributed to several factors:
 - Complex and time-consuming requirements needed to complete care plans
 - Physicians' lack of awareness that these care plans are reimbursable
- Lack of proper discussions on cognitive decline between physicians and patients according to the Alzheimer's Association only 3% of primary care physicians proactively discuss cognitive decline with patients during routine health visits



Physicians, PAs, & NPs

Clinicians can provide and bill for care planning services

- According to a 2016 JAMA report, it is estimated that clinicians needed to create 35 million care plans annually for an estimated 18 million patients
- Today, due to complexity of CMS requirements there has been very limited adoption of cognitive care plans



- uMETHOD has the first AI-powered platform to produce detailed cognitive care plans
- Analyzes patient's lab tests, health history, lifestyle habits, medications, and more
- Identifies treatable causes of cognitive decline that are active in the patient
- Provides patient-specific care plan that recommends to clinicians and patients effective combinations of treatments, lifestyle changes, supplements and medications



BrainCheck focuses on cognitive assessments, but has clinical decisionmaking and cognitive care planning tools

- Cognitive assessment tests memory, attention and executive function
- Clinical decision-making scores patients' cognitive health, tracks performance, likelihood of impairment and more
- Care planning tool helps providers build, document and deliver comprehensive care plans

September 2023

Pharmaceutical Treatments for Cognitive Decline

Five therapies aim to improve symptoms, but do not affect the underlying brain changes that cause symptoms, nor do they alter the course of the disease

Can be prescribed as monotherapies or combination therapies¹



The FDA has approved two drugs which alter the course of the disease, while one other drug is seeking approval by the end of 2023 – all are immunotherapies that target beta-amyloid plagues

While trials have exhibited signs of slowing the pace of CD progression, these drugs have been linked to serious • side effects, such as brain swelling & brain bleed



(lecanemab-irmb)

Donanemab

Successful drug approvals point to a better understanding of Alzheimer's-related biology, laying the foundation for more productive drug development programs

- FDA Accelerated Approval in 2021
 - Produced by Eisai and Biogen
 - Annual list price \$28,000³
 - Covered by Medicare only for those in clinical trials
 - Shown to reduce beta-amyloid plagues
 - Approved by the FDA in July 2023
 - Produced by Eisai and Biogen
 - Annual list price \$26,500⁴
 - Covered by Medicare
 - Shown to slow disease progression by 27% over an 18-month period
 - Seeking FDA approval by end of 2023
 - Produced by Eli Lilly
 - Results have shown that treating patients who are in the earliest stages of Alzheimer's can slow disease progression by 40-60%⁵

Source: (1) National Institute on Aging - How is Alzheimer's Disease Treated, (2) Alzheimer's Association - Alzheimer's disease drug development pipeline: 2023 (3) National Council on Aging -What You Need to Know About Aduhelm, (4) Alzheimer's Association – Lecanemab Approved for Treatment of Early AD (5) CNBC – Eli Lilly expects FDA decision on Alzheimer's treatment donanemab 13 by end of the year

As of 2023, the FDA has approved 7 drugs for the treatment of Alzheimer's¹...

Aduhelm and Legembi represent the first new Alzheimer's drugs to gain FDA approval in nearly 20 years²...


Pharma Companies Targeting Alzheimer's

Pharma companies have increased their focus on developing medications targeted at preventing, delaying, or improving symptoms of Alzheimer's disease through a variety of pathological processes

As of January 2023, there were **187 trials** assessing **141 unique treatments** for Alzheimer's¹...

While amyloid-targeting therapies remain a prominent focus, the Alzheimer's drug development pipeline is diversifying across several targets and treatment modalities...

Given the complexity of Alzheimer's, it is likely that future treatments will involve a cocktail of expensive therapeutics



Selected Memory Care Companies

Most large skilled nursing and assisted living operators such as Brookdale Senior Living, NHC, and Sunrise Senior Living have memory care service lines, while other companies have a dedicated focus on memory care

	Company	Description	Selected Investors
	ARTIS SENIOR LIVING	Operator of 25 memory care and assisted living communities across 11 states. Most communities are focused on delivering care for individuals with Alzheimer's disease and other dementias	Undisclosed
	SILVERADO	Provider of assisted living and home care services for Alzheimer's patients and senior citizens. Services include hospice care, care management, memory care assisted living, and in-home companion care. 28 locations across 10 states.	Welltower; Artemis Real Estate Partners
	Abe's Garden [®] Community	Senior lifestyle community and home care provider offering independent living, assisted living, residential memory support, and non-residential community-based services.	Privately Held
ſ	rippl	Behavioral healthcare company focused on Alzheimer's and other dementias. Empowers clinicians to adopt a new care model using disruptive technology to provide virtual care services to those experiencing cognitive decline.	ARCH Venture Partners; F-Prime Capital; General Catalyst; GV; 1843 Capital; Mass General Brigham Ventures; Rsquared; City Light Capital
	Helpers	Professional home care services offering proprietary, specialized programs for those with Alzheimer's and dementia, Parkinson's and other chronic diseases. Franchises located across 42 states.	Advocate Aurora Enterprises

Alternative Site

Memory Care

Source: Company Websites, Pitchbook

Contact Us

Avondale Partners is an investment banking firm focused primarily on the healthcare services and healthcare technology sectors. Headquartered in Nashville, TN, we have completed over 200 transactions totaling more than \$40 billion in value. We differentiate ourselves by achieving superior outcomes for our clients through senior-level attention from bankers averaging more than 20 years of experience.

Avondale Partners Senior Team



Jonathan Morphett Managing Partner jmorphett@avondalepartnersllc.com Office: 615.467.3533 Mobile: 615.594.5905



Philip Krebs Managing Partner pkrebs@avondalepartnersllc.com Office: 615.467.3482 Mobile: 615.403.6530



Pat Shepherd Managing Partner pshepherd@avondalepartnersllc.com Office: 615.467.3515 Mobile: 615.430.2282



Allison Brown Managing Director abrown@avondalepartnersllc.com Mobile: 312.952.2078



John Patterson Managing Director jpatterson@avondalepartnersllc.com Mobile: 908.403.2135



Wes Chapman Managing Director wchapman@avondalepartnersllc.com Mobile: 603.252.7340

More information can be found on our website at www.avondalepartnersllc.com